**I Title:**

T-cell subsets in the skin and their role in inflammatory skin disorders

**II Short title:**

T-cell subsets in inflammatory skin disorders

**III Authors:**

Inge KORTEKAAS KROHN1, 2, Joeri L. AERTS3, Karine BRECKPOT4, Cleo GOYVAERTS4, Edward KNOL5,6, Femke VAN WIJK5, Jan GUTERMUTH1, 2

**IV Affiliations:**

1 Vrije Universiteit Brussel (VUB), Skin Immunology & Immune Tolerance (SKIN) Research Group, Laarbeeklaan 103, 1090, Brussels, Belgium

2 Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Universitair Ziekenhuis Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium

3 Vrije Universiteit Brussel (VUB), Neuro-Aging and Viro-Immunotherapy (NAVI) Research Group, Laarbeeklaan 103, 1090, Brussels, Belgium

4 Vrije Universiteit Brussel (VUB), Laboratory for Molecular and Cellular Therapy (LMCT), Laarbeeklaan 103, 1090, Brussels, Belgium

5 Center for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

6 Department Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands

**Corresponding author:**

Prof. Dr. Inge Kortekaas Krohn

SKIN Research Group

Department of Dermatology

Vrije Universiteit Brussel (VUB)

Laarbeeklaan 103, Building D, Room D148

1090 Brussels, Belgium

Tel.nr.: +32 2477 4244

E-mail: [ingekortekaas@gmail.com](mailto:ingekortekaas@gmail.com)

**Word count: 5395**

**Statement of contribution:**

All authors contributed to the completion of this review by writing a paragraph about their field of expertise. Everyone contributed to the preparation of the figures and/or tables. The content was discussed, revised and approved by all authors.

**Acknowledgments:**

IKK is holder of the Fonds Wetenschappelijk Onderzoek (FWO) Post-Doctoral mandate (12W2219N) and a ‘Type 2 Innovative Grant’ (2018) from Sanofi Genzyme.

JG received research grants and/ or served as advisor/ speaker for Janssen, Sanofi, LEO Pharma, Mylan, Lilly, Abbvie and Pfizer. He is member of the Advisory Board of Sanofi.

KB holds an young investigator award of the Melanoma Research Alliance (grant number 509516, grant identifier https://doi.org/10.48050/pc.gr.75694.

**VI Abstract and keywords:**

T-lymphocytes (T-cells) are major players of the adaptive immune response. Naive T-cells are primed in the presence of cytokines, leading to polarization into distinct T-cell subsets with specific functions. These subsets are classified based on their T-cell receptor profile, expression of transcription factors, surface cytokine and chemokine receptors, and their cytokine production, which together determine their specific function. The role of T-cells in disease pathophysiology depends on the underlying mechanism and signaling???. This review provides an overview of the various T-cell subsets and their function in several inflammatory skin disorders ranging from allergic inflammation to skin tumors. Moreover, we highlight similarities of T-cell responses across different skin disorders, demonstrating the presence of similar and opposing functions for the different T-cell subsets. Finally, we discuss the effects of currently available and promising therapeutic approaches to harness T-cells in inflammatory skin diseases for which efficacy next to unwanted side-effects provide new insights into the pathophysiology of skin disorders.

Words: 169 🡪 nu 157

**Keywords**: inflammatory skin disorders, T-cells, T-cell subsets, skin diseases

**VII Main text**

**1 Introduction**

The human skin is a multifunctional organ that is essential for systemic homeostasis. Epidermal barrier formation provides a first line of defense against exogenous threats, including microbial and physical agents such as radiation and water loss. Additionally, it actively contributes to immune responses as a sentinel organ via the release of cytokines and chemokines that alarm immune cells in case of skin damage or infection. Epidermal keratinocytes are known to produce thymic stromal lymphopoietin (TSLP) and interleukin (IL)-33 in response to environmental signals, which activates innate lymphoid cells (ILCs), T-lymphocytes (T-cells), mast cells (MCs) and eosinophils.

This review focusses on the various cutaneous T-cell subsets and their role in inflammatory skin disorders, and skin tumors. T-cell subsets orchestrate disease pathophysiology by the production of particular cytokines, which in turn affects interactions with other immune cells, such as B-cells, eosinophils, neutrophils, and MCs. Therefore, these adaptive immune responses play a central role in the many inflammatory skin diseases, but also in infections and skin cancer. Additionally, currently available T-cell targeted therapies and future directions will be addressed.

**2 Role of T-cell subsets and innate lymphoid cells in healthy skin**

**2.1 Conventional and unconventional T-cells**

Conventional T-cells express a highly diverse T-cell receptor (TCR) repertoire, consisting of α and -chains, which determine antigen specificity. They are further classified into CD4+ and CD8+ T-cells, depending on respective co-receptor expression. Upon recognition of cognate antigens, naive T-cells from both lineages differentiate into effector T-cells that exert specific functions depending on their differentiation program. CD4+ T helper (Th) subsets are primarily classified based on their master transcription factor profile and cytokine production, including T-BET, interferon (IFN)-, and tumor necrosis factor (TNF)- for Th1, GATA-3, IL-4 and IL-13 for Th2, IRF 4 and IL-9 for Th9, ROR IL-17a and IL-17F for Th17, AHR and IL-22 for Th22, and BCL-6 and IL-21 for T follicular helper (Tfh) cells (**Figure 1**). Another characteristic Th-cell feature is distinct expression of chemokine receptors, which enable T-cell recruitment to tissues. Naive T-cells express CXCR4 and CCR7, which mediate spatial accumulation with dendritic cells (DCs) in lymphoid tissues. Upon activation and polarization, CXCR4 and CCR7 are downregulated, while the expression of other chemokine receptors is upregulated. For instance, co-expression of CXCR3 and CCR5 is upregulated by Th1 cells, while CCR3 and CCR4 are predominantly expressed on activated Th2 cells (**Table 1**). Canonical CD4+ T-cell subsets also include *FOXP3-*expressing regulatory T-cells (Tregs) that are mostly thymus-derived but may also be induced in the periphery under specific circumstances, and exert suppressive functions by IL-10 and transforming growth factor (TGF)-. For CD8+ cytotoxic T-cells (Tc) a similar, albeit less demarcated classification exists with Tc1, Tc2, Tc9, Tc17, Tc22 (Reviewed in (1,2)) (**Figure 1, Table 1**). Importantly, a rapidly growing body of single-cell sequencing and epigenetic data demonstrates substantial heterogeneity and plasticity among T-cell subsets (3,4), suggesting that current T-cell subset working models do not reflect the complete T-cell differentiation complexity.

A proportion of effector CD4+ and CD8+ T-cells becomes long-lived by differentiating into self-renewing memory T-cells. Central memory T cells (TCM) circulate in blood and traffic through lymphoid tissues, while effector memory T-cells (TEM) enter and patrol peripheral tissues, including skin (5). It has become clear that a significant part of tissue T-cells can become resident (6). Tissue-resident memory T-cells (TRM) provide local surveillance and are retained in tissues (7,8).

Besides conventional T-cells, several unconventional T-cell subsets have been described such as  T-cells, natural killer (NK)T-cells, and Mucosal Associated Invariant T (MAIT) cells. These less abundant T-cell subsets have in common that they express semi-invariant TCRs, recognize specific (often non-peptide) antigen classes, possess innate-like properties, and are enriched in barrier tissues where they play a role as pathogen sentinels (9).

**2.2 T-cells in the skin**

Under steady state conditions, the human skin harbors billions of T-cells, largely composed of resident next to recirculating memory T-cells (8,10,11). In the skin, Langerhans cells and DCs are the most important professional antigen-presenting cells (APCs) which act as gate keepers, presenting captured antigens on major histocompatibility complex (MHC) proteins to naive T-cells. The latter takes place in skin draining lymph nodes, after which T cells become activated and primed for skin-homing, orchestrated by specific chemokine receptors (CCR4, CCR10, and CCR8) (12,13) next to cutaneous lymphocyte antigen (CLA), a ligand for E- and P-selectin, and a glycovariant of P-selectin glycoprotein ligand-1 (14) (**Figure 2A**).Subsequently, T-cells can activate various differentiation programs depending on their surroundings. After T-cells encounter specific antigens, this can lead to clonal proliferation, cytokine release and activation of other immune cells (e.g. B-cells) or cells in their local environment (e.g. keratinocytes). During inflammation, T-cell migration into the skin is more permissive and enhanced via local pro-inflammatory chemokine and cytokine production, such as recruitment of CXCR3+ T-cells by local CXCL9, CXCL10, and CXCL11 production.

In the skin, a part of the recruited T-cells further develops into TRM. Markers that are most widely used to identify TRM in the skin are CD69, CD103 and CD49a. Expression of CD69 is important for tissue retention as it antagonizes S1PR1, required for migration of T-cells out of tissues (15). However, CD69 expression is not an absolute requirement for TRM maintenance as also CD69- TRM populations have been described. In healthy human skin, most of the TRM in the dermis are CD4+CD69+CD103− cells, while the epidermis contains a mixed population of CD4+ and CD8+ CD69+CD103+ TRM (10), with CD8+CD49a+ T-cells poised for cytotoxic function (16). TRM development is presumed to be driven by antigen exposure, together with cytokines and chemokines in the local tissue environment. TGF-β has been shown to drive TRM generation (by downregulation of the transcription factors Eomes and T-bet), and to induce CD103 expression. Recent studies in mice suggest that TRM can sustain themselves in the skin via local proliferation (17), and that long-term survival of TRM depends on IL-15 and lipid uptake (18–20). In general, TRM exhibit an elevated inflammatory cytokine and cytotoxicity-associated transcriptional profile compared with circulating memory T-cells, suggesting a poised state for rapid effector function upon activation (21). Additionally, CD4+ and CD8+ TRM also express multiple inhibitory surface molecules, indicating that T-cell function is tightly regulated (21). TRM from different tissues share a core signature, yet tissue-specific adaptations and inter-tissue-heterogeneity exists (21). In steady state, skin TRM are thought to play a role in tissue homeostasis, while upon local (re)infection or under chronic inflammatory conditions, TRM rapidly accumulate in the skin, produce inflammatory cytokines (e.g. IFN-IL-22, IL-17) and can exert cytotoxic functions (16,22–24). Also resident Tregs are located in the skin. In murine skin, Tregs have been demonstrated to facilitate wound healing and modulate hair follicle stem cells (25,26) and also in humans, cutaneous Tregs display a tissue repair signature (27).

In mice, T-cells that are not restricted to classical MHCs (T-cells, MAIT-cells, and CD1-reactive T-cells) play an important role in skin immunity and homeostasis (reviewed in (28)). In humans, these T-cell populations (especially the  T-cells) are less abundant and therefore their role is less clear.

**2.3 Innate lymphoid cells**

In mice and men resident ILCs contribute to skin homeostasis and immunity via cytokine secretion and regulation of innate and adaptive immune cells. Despite their lack of antigen-specific TCRs, ILCs show parallels with conventional T-cell subsets, and therefore, ILCs are discussed briefly: ILCs are mainly present at barrier surfaces, which reflects their role as first line immune regulators. Under homeostatic conditions ILCs reside in low numbers in the dermis and are involved in tissue repair. They rapidly respond to signals in the microenvironment via cytokine production (reviewed in (29,30)). Several subsets of ILCs are characterized (reviewed in (29)) (**Table 1**): Type 1 ILCs (ILC1) are the innate variant of Th1, whereas NK-cells are the innate equivalent of Tc1, which are present in the dermis, intestines, liver and lung. ILC1s are activated by IL-12 and IL-18, and produce IFN-γ. As a response to microbial exposure, these cells increase in number and initiate a pathogen-specific immune response (31) (reviewed in (32)). Type 2 ILCs (ILC2s) are the innate equivalents of Th2 and the most abundant ILC subtype in the skin, where they reside in close proximity of MCs and keratinocytes, and respond to IL-25, IL-33, TSLP or prostaglandin (34,35). They are an important source of IL-5, IL-13, and also produce amphiregulin (a cell growth signal, survival, migration and immune modulation) (33). Due to their mediator profile, ILC2 act as early responders in allergic inflammation. Lymphoid tissue inducer cells (Lti) represent the Th17 cells and type 3 ILCs (ILC3s) correspond to Th22 (**Table 1**). ILC3s are activated by IL-1β, IL-23, and aryl hydrocarbon receptor ligands, and produce IL-17A, IL-17F, IL-22, TNF-α and granulocyte-macrophage colony-stimulating factor (GM-CSF).

**3 The role of T-cells in inflammatory skin diseases including T-cell therapies**

**3.1 Allergic inflammation**

External allergens can initiate allergic sensitization with a Th2-skewed T cell response and immunoglobulin E (IgE) antibody-production, resulting in acute and chronic cutaneous inflammation. Upon exogenous allergen exposure, APCs migrate to local lymph nodes to prime naive T-cells, which differentiate in the presence of IL-4 into allergen-specific Th2-cells. Th2-cells induce an IgE class switch of B-cells, which leads to MC sensitization. In acute type-I hypersensitivity reactions, allergen re-exposure induces rapid MC degranulation. In the late phase response, activated antigen-specific Th2-cells produce pro-inflammatory cytokines (**Figure 2B**). While IL-4, IL-13 and histamine can contribute to an impaired skin barrier function (36–38), IL-5 and IL-9, produced by Th9-cells, attract eosinophils. IL-13 regulates inflammation via stimulation of IgE-producing B-cell proliferation, fibrosis, and recruitment of inflammatory cells and changes in the skin microbiome (38). IL-31 elicits pruritus by binding to its receptors on sensory nerves in the skin. Additionally, ILC2s produce IL-5 and IL-13 in response to prostaglandin and leukotrienes secreted by MCs or IL-33 and TSLP from keratinocytes (39). Recently, the “barrier hypothesis” was introduced, suggesting that increased epithelial barrier-damage can be related to industrialization, urbanization and lifestyle changes. This implies that not only allergens, but also infections, pollutants and other environmental triggers impact allergic inflammation (40).

**3.2 Atopic dermatitis**

Atopic dermatitis (AD) is a common skin disease affecting up to 20% of children and approximately 5% of adults (41). It is characterized by impaired skin barrier function and inflammation of the skin resulting in pruritus and formation of eczematous areas. The disease course of AD can be affected by external factors, like allergens (e.g. house dust mites), resulting in IgE-mediated allergic skin inflammation, as described above. Many patients with AD exhibit chronic skin inflammation in the absence of sensitization to external allergens, pointing out the importance of endogenous factors which can contribute to persistent inflammation via T-cell activation. Therefore, both local as well as systemic immune mechanisms can act as underlying causes.

A hallmark in AD is a marked T-cell influx in the epidermis at the site of the itchy eczema (42). Notably, healthy skin contains twice as many T-cells and atopic skin even thrice as many as peripheral blood (43). This implies that although research on cutaneous T-cells is technically more challenging than on T-cells in peripheral blood, the analysis of peripheral blood T-cells may not fully represent the immunopathology impact of T-cells in AD. The majority of T-cells are CD4+ with a dynamic Th-subset pattern: from Th2 and ILC2s in more acute, towards Th1/Th2 in more chronic inflammatory AD conditions (44) (**Figure 2C**). Keratinocyte apoptosis in eczema lesions is linked to IFN-ɣ release and FAS expression by epidermal CD4+ T-cells (45). More recent studies also describe the presence of IL-17, IL-21 and IL-22 releasing CD4+ T-cells in atopic skin (46,47), with a more profound Th17-profile in the Asian population (48). IL-22 induces keratinocyte proliferation and epidermal thickening in AD. Although CD8+ T-cells comprise up to 30% of the skin T-cell population in AD, mostly in the epidermis, knowledge on this population is scarce. Skin CD8+ T-cells in AD are a potent source of IL-13, IFN-ɣ and IL-22 (49), suggesting a pathogenic contribution to inflammation in AD. Also, an immunoregulatory role for this T-cell population is suspected and CD8+ T-cell infiltration in the skin is marked in early atopy patch test reactions (50).

Skin T-cell activation is achieved in multiple ways: by release of innate type cytokines, as well as antigens by epidermal cells. It has also been shown that, although the skin T-cell population is polyclonal, allergen-specific long-lived T-cell clones can be obtained from skin (51). In addition, skin T-cell reactivity has been demonstrated for microbial and autoantigens (52). Patients with AD can have a Th2-induced decreased production of antimicrobial peptide (AMP), leading to an increased risk for colonization with *S. aureus* or other pathogens (49). During cutaneous herpes simplex virus 1 infections, nociceptive sensory neurons reduce neutrophil skin infiltration, promoting the induction of an antiviral CD8+ T-cell response (53).

The characteristic increase in T-cell number in skin can be due to local proliferation, and selective T-cell skin homing. More than 90% of the skin T-cells express CLA, which is a selective adhesion molecule (54). In addition, also CCR10 and CCR4 chemokine receptors are expressed on the majority of skin-dwelling T-cells. The ligands for CCR4, CCL17/TARC, and for CCR17, CCL27/CTACK are specifically increased in the blood of AD patients (55,56). The CCL17/TARC serum concentration is related to the AD severity within individual patients and is an informative biomarker in AD (57).

Several pharmacological interventions indicate the crucial role of T-cells in human AD. For example, cyclosporine (CsA), which acts on T-cells specifically by blocking calcineurin activity, is effective in a large subgroup of severe AD-patients (58). Recently, treatment with antibodies, specifically targeting immune players, provided further insight in the role of T-cells and their products (**Table 2**). Regarding the role of type 2 responses in AD, it was found that blocking IL-5 by mepolizumab does not improve AD (59). The effect of blocking IgE by anti-IgE (omalizumab) is still inconclusive (60), especially because high serum levels of IgE in AD may limit the effectiveness of omalizumab. A profound clinical effect on AD is observed by dupilumab-mediated blocking of IL-4Rα, which prevents binding of IL-4 and IL-13, indicative for their crucial role in AD (61–63). Depleting IL-13 has modest to sustained effects on AD (64–66). Binding of IL-4 to IL-4Rα and the γ-chain (type I receptor) results in signaling via Janus kinase (JAK)1, JAK3 and signal transducer and activator of transcription (STAT) 6. IL-4 and IL-13 share the IL-4Rα subunit, so both cytokines can bind to the type II receptor. The importance of IL-4/IL-13 in AD pathophysiology is also supported by the proven efficacy of JAK1/JAK3 inhibitors (67–71). Reduction in pruritus was obtained using a monoclonal antibody against IL-31 (72). As previously stated, in some AD patients also a local Th17 population is described. However, targeting IL-17 did not have a significant effect on AD (73).

For improved personalized treatment of AD, disease endotyping can be an effective approach. Different immunologic backgrounds that underlie AD became clear via cluster analysis, which identified 4 serum biomarker-based clusters; "skin-homing chemokines/IL-1R1-dominant", "Th1/Th2/Th17-dominant", "Th2/Th22/PARC-dominant", and a "Th2/eosinophil" cluster (74). Another endotype that has been proposed is the presence of autoreactive T-cells and IgE autoantibodies directed to autoantigens in the skin (75,76). Due to chronic skin inflammation and skin damage, epitope spreading may activate autoimmune processes and bystander activation of (autoreactive) T-cells, which can activate B cells to produce autoreactive IgE antibodies, resulting in an IgE-mediated autoreactive response (77,78). However, to date it is unclear whether the presence of autoreactive T-cells and IgE autoantibodies form a distinct cluster, arguing for more research into its clinical relevance.

In conclusion, marked T-cell activation in AD is observed systemically and locally. Although the T-cell phenotype is dynamic, Th2-cell functions seem dominant in this pathology.

**3.3 Psoriasis**

Psoriasis is a chronic inflammatory skin disease characterized by scaly erythematous plaques (79). Psoriasis affects approximately 2–4% of the population and may also involve the joints. Th17, Th1-cells and CD8+ T-cells (Tc17) are the main players in disease pathophysiology, and also MAIT-cells may act as an alternative source of IL-17A in psoriasis affected skin (80). IL-17 and IL-22 modulate gene expression in keratinocytes. IL-17 was shown to upregulate the expression of immune cell chemo-attractants that contribute to psoriasis pathogenesis and IL-22 regulates terminal keratinocyte differentiation and epidermal thickening (79). Monoclonal antibodies that target IL-17 (**Table 2**) were shown to be effective for controlling psoriasis (81–84). Additionally, TNF-inhibitors (**Table 2**) can improve the symptoms (85), although, TRM cells still reside in recovered skin lesions.

ILC3s are increased both in the skin and blood of patients with psoriasis (33,86,87), and ILC3 numbers correlate with disease severity (80). IL-23 is produced by activated DCs, macrophages, or monocytes, but also by ILCs and γδ T-cells. IL-23 is also important for the maintenance and expansion of IL-17A-producing T-cells. IL-12, also produced by DCs, and a close family member of IL-23, sharing its p40 subunit and part of its receptor, is crucial for NK-cell activation and Th1-cell differentiation (**Figure 2D**). The contribution of IL-12 and IL-23 to psoriasis pathophysiology is reflected by the efficacy of biological antagonists, of which several have been approved to treat psoriasis (88–91) (**Table 2**).

**3.4 Chronic spontaneous urticaria**

In the skin of chronic spontaneous urticaria (CSU) patients, lesions are infiltrated with T-cells that reside near MCs. CSU is further characterized by increased expression of IL-33, IL-25 and TSLP, which can trigger MCs, leading to vascular leakage and an inflammatory response (92). Around 50% of CSU patients have a positive autologous serum skin test (ASST+) (reviewed in (93)). IgE or IgG autoantibodies against thyroid antigens, double stranded DNA or IL-24, have been detected and are associated with disease activity and with predictive relevance (94–97). IgG autoantibodies and autoreactive CD4+ T-cells against FcεRIα have also been identified in peripheral blood and were inversely correlated to a Th1-cytokine response, suggesting that IFN-γ is present in early stages and auto-reactivity develops in later stages of CSU (98). The presence of atopy and/or a positive response to serum auto-reactivity was linked with differences in Th1, Th2, Th17 and Th22 cytokine expression patterns, suggesting that several mechanisms underlie the emergence of urticaria (99). Expression of IFN-γ, IL-2 and IL-21 is associated with auto-reactivity (99). These cytokines are regulated by the JAK/STAT pathway and may thus be of importance for therapeutic approaches (**Table 2**). Targeting IgE with omalizumab or ligelizumab are highly effective treatments (100,101). Several off-label treatments of CSU patients with dupilumab, as well as IL-5 receptor antibodies and IL-5 antibodies have been effective, indicating a role of Th2 cell products in CSU (REF)

Th17, Tc17 and MCs produce IL-17A. Increased numbers of Tc1 and Tc17 were observed in ASST+ compared to ASST- patients and healthy controls (102). Also, elevated frequencies of Th17 and IL-17 serum levels have been associated with disease severity, which makes IL-17 a potential target in CSU. In response to secukinumab, an anti-IL-17A antibody, a reduced disease activity was found in patients with CSU (103). Although, some studies showed no difference in IL-17 serum levels or even lower numbers of Th17-cells compared to healthy controls (102,104). Finally, reduced numbers of peripheral blood Tregs were found in chronic urticaria patients, yet their specific function in CSU still warrants further investigation (104).

**3.5 Connective Tissue Diseases**

Connective tissue diseases include several disorders, such as rheumatoid arthritis, scleroderma, lupus, and dermatomyositis. Patients present multi-organ involvement, including joint pain, hematologic aberrations, kidney dysfunction, and often skin signs.

In patients with connective tissue disease, reduced numbers of peripheral blood Tregs were found compared with healthy controls. Frequencies of Tregs inversely correlated with disease activity and the presence of autoantibodies (105). Presence of anti-melanoma differentiation-associated gene 5 (MDA5, a cytoplasmic RNA sensor) autoantibodies and a high age at disease onset are factors for poor prognosis in patients with polymyositis and dermatomyositis with interstitial lung disease (106). Serum levels of IFN-α and ferritin were increased in the anti-MDA5 antibody positive patients with dermatomyositis and can be used as biomarkers (107). In response to rituximab therapy (monoclonal anti-CD20 antibody), these patients improved skin rash and interstitial lung disease (108). Nintedanib inhibits both nonreceptor tyrosine kinases and receptor tyrosine kinases, which reduced progression of interstitial lung disease in patients with systemic sclerosis (109). Additionally, JAK inhibitors have been suggested as an alternative treatment for dermatomyositis (110), as effects of IFNs are mediated through the JAK/STAT pathway. In patients with dermatomyositis, T-cell numbers were decreased, which was associated with interstitial lung disease (111).

In the pathophysiology of connective tissue diseases, an imbalance of TCR-signaling and reduced expression of FoxP3 may underlie disease pathophysiology. Decreased tolerance resulting from lower Treg numbers might be central, pinpointing Treg activation as an interesting therapeutic approach.

**3.6 Other inflammatory skin diseases**

In cutaneous lichen planus, key inflammatory players are IFN-γ and IL-21 (112). IL-21 is produced by CD4+ Tfh and NKT-cells. Upon binding to its receptor (IL-21R), the JAK(1/3)/STAT(3/1/5)-pathway is activated, which augments T-bet and STAT4 expression in T-cells and IFN-γ production. JAK inhibitors, such as tofacitinib, can be an effective therapy to treat lichen planus (112,113).

In contrast to connective diseases or other inflammatory skin diseases, the causative cutaneous antigens of bullous pemphigoid are well described. Autoreactive IgG or IgE autoantibodies to the antigens BP180 or BP230 induce pruritic eczematous or urticarial lesions and subepidermal blister formation, mainly in elderly patients (114–116). In addition, Th17-cells and autoreactive Th1/Th2-cells have been observed including a mixed spectrum of cytokines, such as IL-17, IFN-γ and IL-5 (117). Moreover, Th2 cytokines were found in blisters, which point to an additional role of Th2-cells, a fact that is further substantiated by the identification of anti-BP180/230 IgE autoantibodies (118,119).

Alopecia areata is a chronic, relapsing, skin disease leading to patchy hair loss that can reversibly affect small areas of the scalp or trunk, but can also progress to large, therapy resistant areas with complete hair loss. CD8+ T-cells are regarded as main causative cells in alopecia areata, however, a recent murine study identified a mixed profile of both CD4+ and CD8+ T-cells (120). Classical treatments include topic or systemic corticosteroids, but recently JAK1/3 inhibition using tofacitinib and ruxolitinib proved to be a highly effective treatment (121).

Vitiligo is a patchy, progressive depigmentation disorder of the skin. There are several hypotheses on vitiligo pathogenesis, of which a CD8+ T-cell-mediated destruction of melanocytes (122). In a murine model, CXCL10 neutralization improved the disease resulting in renewed pigmentation, suggestive for a critical role of CXCL10 in vitiligo (123). Recently, evidence for Th9-cells was observed by flow cytometry (124). In a phase 2 trial, treatment with ruxolitinib cream showed renewed pigmentation of the lesions, which implies an effective treatment approach for vitiligo (125).

**3.7 Melanoma and non-melanoma skin cancers**

Skin cancer can take many forms and shapes both with respect to pathophysiology and prognosis. Skin cancers can be broadly divided into melanoma and non-melanoma skin cancers (NMSCs), represented by basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). NMSCs are responsible for only a small fraction of mortality. In contrast, melanoma, resulting from uncontrolled growth of melanocytes, represents only a minority of the skin cancer cases yet is responsible for the majority of skin cancer-related deaths (126,127). There is compelling evidence that melanoma can be killed by T-cells. Over 50 years ago, dermal lymphocyte reactions were described at early stages of primary melanoma growth (128). Moreover, clonal T-cell expansion is observed in regressing melanoma (129,130), while T-cell infiltration in stable and even progressive disease, is correlated to prolonged survival and lower risk of metastasis (131,132). Characterization of these T-cells has resulted in identification of melanoma-associated antigens and neoantigens that allow T-cells to selectively kill melanoma cells (135,136) (133,134). Specifically, CD8+ T-cells can recognize antigen-derived peptides presented via MHC-I on melanoma cell surface after which they can exert their cytotoxic function using Fas Ligand, perforin and granzyme B, and cytokines such as IFN- and TNF- (**Figure 2E**) (137). Additionally, IFN--secreting Th1-cells can recognize antigen-derived peptides in MHC-II and aid CD8+ T-cell activation. These CD4+ T-cells can also kill melanoma cells that show expression of MHC-II and their cognate antigen (138,139), using IFN-γ, perforin and granzyme B, rather than Fas Ligand, as their weapon of choice (140,141). The important role of Th1-cells in rejecting melanoma cells, independent of MHC-II expression, is further evidenced by their ability to stimulate macrophage-mediated cytotoxicity (141). The role of Th9 and Th17 subsets in melanoma is increasingly explored. These Th-subsets merit attention as they can exert direct cytotoxic functions through production of cytokines and granzyme B (142–145). Th9-cells, similar to Th1-cells, exert multiple supportive antitumor activities, including recruitment and/or activation of innate immune cells like MCs (142), DCs (143) and NK-cells (146). Th17-cells can also facilitate CD8+ T-cell recruitment, yet can also promote angiogenesis and tumor proliferation, and even adopt a Treg-phenotype, thereby opposing tumor rejection (147). CD4+CD25highFoxp3+ Tregs represent a predictive marker for tumors that are escaping immune-mediated killing as they possess a multitude of T-cell suppressive mechanisms, e.g. TGF-β production (148,149)(150,151).

Unconventional T-cells remain less well studied. γδ T-cells that are attracted to melanoma via the CCR2/CCL2-pathway have antitumor traits (147). These γδ T-cells can recognize tumor-specific ligands neglected by conventional αβ T-cells in an MHC-independent as well as -dependent manner (152,153). The majority of melanoma-infiltrating γδ T-cells shows an effector memory and terminally differentiated phenotype, and a higher rate of γδ T-cell infiltration, in particular of Vδ2 T-cells, correlates with early stage melanoma and absence of metastasis (154). Therefore, γδ T-cells are considered interesting candidates for adoptive T-cell therapy (155). Yet, the function of γδ T-cells should be carefully studied, as Vδ1 T-cells with immunosuppressive activity have been found in melanoma as well (156). In melanoma patients treated with CTLA-4 blocking antibodies, an increase in Vδ2 versus Vδ1 T-cells was linked to good versus poor survival (157). NKT-cells are also studied in melanoma. As they recognize lipids restricted by a non-classical class I-like molecule CD1d, they are also considered unconventional T-cells (158). The majority of NKT-cells in mouse and human are invariant NKT-cells that recognize α-galactosyl ceramide (α-GalCer). A final understudied unconventional T-cell subset is represented by MAIT-cells. In metastatic melanoma-patients treated with anti-PD-1 therapy, an increase in CD8+ T-cells and MAIT-cells was demonstrated specifically in responders. As patients with >1.7% of MAIT-cells among the peripheral CD8+ T-cell population showed a better response to treatment, MAIT-cells may be considered a biomarker for melanoma patients responding to anti-PD-1 therapy (159,160) (**Table 2**).

Various approaches to harness the immune system in the fight against melanoma are under investigation, from immunization strategies, including DCs, peptide (161,162) and nucleic acids (163) vaccines and the use of oncolytic viruses, exemplified by T-VEC ((164) reviewed in (165)), to cytokine therapy ((166–168) reviewed in (169)), inhibition of co-inhibitory ((170) reviewed in (171,172)) and/or stimulation of co-stimulatory (173–176) immune checkpoints, and adoptive T-cell therapies including engineered T-cells (177). These approaches mainly focus on enhancing the number and activity of CD4+ Th1 and CD8+ T-cells, while some yet not all also reduce the activity of Tregs. Approaches that also harness NKT-cells are under way. The latter have shown promise in preclinical studies (178,179), be it with suboptimal results, leaving room for improvement (180,181).

Without a doubt, immune checkpoint inhibition (ICI) of the CD80/86-CTLA-4 as well as the PD-1-PD-L1 pathway, has delivered and holds promise for other immunotherapies to treat melanoma. Yet its effectivity is currently hampered by the installation of inherent and adaptive resistance mechanisms, that may vary considerably among patients (182–185) (reviewed in (186)). Moreover, 33-50% of melanoma patients treated with ICIs develop cutaneous immune-related adverse events (iRAEs) that can unfold as local or widespread rashes that can present as eczema, psoriasis, depigmentation and other skin disease variants, indicating the role of T-cell subsets in these conditions ((187–190) reviewed in (191)) (192). Notably, a positive correlation between melanoma-associated leukoderma (depigmentation) and survival after immunotherapy has been described (reviewed in (193)).

**3.8 Virus-induced skin cancers**

Various oncogenic viruses have been identified, of which several are involved in skin cancer. The most prevalent cancer-associated virus is human papillomavirus (HPV), with HPV16 and 18 being the most important strains, causing cervix carcinoma, but also penile, vaginal, anal, and oro-pharyngeal cancer.

Head and neck squamous cell carcinoma (HNSCC) can be divided in HPV+ and HPV- tumors. Overall prognosis of HNSCC is worse than for SCC at other sites of the skin, but HPV+ HNSCC shows a better prognosis than HPV- cancers. Moreover, HPV+ HNSCC respond better to ICIs, which might be attributed to their high-level infiltration of PD-1+ T-cells, as PD-L1 status on the tumors was not different (194). Both for HPV+ and HPV- HNSCC, Treg infiltration is an independent prognostic factor (195). An interesting question that remains to be answered is whether HPV vaccines also protect against HPV+ HNSCC.

Merkel cell carcinoma (MCC) is a rare but aggressive tumor of neuro-endocrine origin. They derive their name from the Merkel cells that can be found in the basal layer of the epidermis and play a role in touch sensation. The underlying cause of MCC is infection with an oncogenic polyomavirus (196). Oncoprotein-specific tumor-infiltrating CD8+ T-cells were prevalent in MCC patients (197). ICI therapy has proven effective in the treatment of MCC, although about 50% of patients remain refractory (198) (**Table 2**). Presence of high numbers of TCM with high TCR diversity was shown to be predictive of good response to ICI therapy (199).

Kaposi’s sarcoma (KS) is a vascular tumor caused by human herpes virus type-8 (HHV-8) and is especially associated with late-stage HIV infections. Although CD8+ T-cell infiltrates were observed in KS lesions, they were not associated with sites of HHV-8 infection (200). Stage-related PD-L1 expression was observed on KS tumors, suggesting that these types of tumors might benefit from ICI therapy (201).

**4 Concluding remarks**

The role of T-cells in inflammatory skin disorders is based on a complex interaction with innate immune cells, B-cells, and other cells in their microenvironment. The various T-cell subsets and their mediators affect activation, migration, differentiation, and function of local tissue and immune cells. This results in a critical involvement of T-cells in skin homeostasis and pathology. Development of effective T-cell targeted biologicals for treatment of inflammatory skin diseases progressed rapidly during recent years, confirming the crucial role of T-cells in inflammatory skin disorders. *Vice versa*, the response to the treatment, or their adverse events, can teach us about the underlying mechanisms and contribute to disease endotyping. Hence, ongoing and improved interdisciplinary research into the role of T-cell subsets in the skin is warranted to further increase our understanding of T-cell functions to pave the way towards novel and effective therapies to harness T-cells in inflammatory skin conditions.

**VIII References:**

1. Eyerich S, Zielinski CE. Defining Th-cell subsets in a classical and tissue-specific manner: Examples from the skin. Eur J Immunol. 2014 Dec;44(12):3475–83.

2. Akdis CA, Arkwright PD, Brüggen M-C, Busse W, Gadina M, Guttman-Yassky E, et al. Type 2 immunity in the skin and lungs. Allergy. 2020 Jul;75(7):1582–605.

3. Mucida D, Cheroutre H. The many face-lifts of CD4 T helper cells. Adv Immunol. 2010;107:139–52.

4. Zhu J. T Helper Cell Differentiation, Heterogeneity, and Plasticity. Cold Spring Harb Perspect Biol. 2018 Oct 1;10(10).

5. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999 Oct 14;401(6754):708–12.

6. Masopust D, Vezys V, Marzo AL, Lefrançois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001 Mar 23;291(5512):2413–7.

7. Sathaliyawala T, Kubota M, Yudanin N, Turner D, Camp P, Thome JJC, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity. 2013 Jan 24;38(1):187–97.

8. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K-I, Dowgiert RK, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol. 2006 Apr 1;176(7):4431–9.

9. Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, Moody DB. The burgeoning family of unconventional T cells. Nat Immunol. 2015 Nov;16(11):1114–23.

10. Watanabe R, Gehad A, Yang C, Scott LL, Teague JE, Schlapbach C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015 Mar 18;7(279):279ra39.

11. Clark RA, Watanabe R, Teague JE, Schlapbach C, Tawa MC, Adams N, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med. 2012 Jan 18;4(117):117ra7.

12. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med. 2001 Nov 19;194(10):1541–7.

13. McCully ML, Ladell K, Hakobyan S, Mansel RE, Price DA, Moser B. Epidermis instructs skin homing receptor expression in human T cells. Blood. 2012 Nov 29;120(23):4591–8.

14. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 1997 Oct 30;389(6654):978–81.

15. Mackay LK, Braun A, Macleod BL, Collins N, Tebartz C, Bedoui S, et al. Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention. J Immunol. 2015 Mar 1;194(5):2059–63.

16. Cheuk S, Schlums H, Gallais Sérézal I, Martini E, Chiang SC, Marquardt N, et al. CD49a Expression Defines Tissue-Resident CD8+ T Cells Poised for Cytotoxic Function in Human Skin. Immunity. 2017 Feb 21;46(2):287–300.

17. Beura LK, Mitchell JS, Thompson EA, Schenkel JM, Mohammed J, Wijeyesinghe S, et al. Intravital mucosal imaging of CD8+ resident memory T cells shows tissue-autonomous recall responses that amplify secondary memory. Nat Immunol. 2018 Feb;19(2):173–82.

18. Mackay LK, Wynne-Jones E, Freestone D, Pellicci DG, Mielke LA, Newman DM, et al. T-box Transcription Factors Combine with the Cytokines TGF-β and IL-15 to Control Tissue-Resident Memory T Cell Fate. Immunity. 2015 Dec 15;43(6):1101–11.

19. Richmond JM, Strassner JP, Zapata L, Garg M, Riding RL, Refat MA, et al. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018 Jul 18;10(450).

20. Pan Y, Tian T, Park CO, Lofftus SY, Mei S, Liu X, et al. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. Nature. 2017 Mar 9;543(7644):252–6.

21. Kumar BV, Ma W, Miron M, Granot T, Guyer RS, Carpenter DJ, et al. Human Tissue-Resident Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid and Mucosal Sites. Cell Rep. 2017 Sep 19;20(12):2921–34.

22. Ariotti S, Hogenbirk MA, Dijkgraaf FE, Visser LL, Hoekstra ME, Song J-Y, et al. T cell memory. Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert. Science. 2014 Oct 3;346(6205):101–5.

23. Park CO, Fu X, Jiang X, Pan Y, Teague JE, Collins N, et al. Staged development of long-lived T-cell receptor αβ TH17 resident memory T-cell population to Candida albicans after skin infection. J Allergy Clin Immunol. 2018 Aug;142(2):647–62.

24. Cheuk S, Wikén M, Blomqvist L, Nylén S, Talme T, Ståhle M, et al. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014 Apr 1;192(7):3111–20.

25. Ali N, Zirak B, Rodriguez RS, Pauli ML, Truong H-A, Lai K, et al. Regulatory T Cells in Skin Facilitate Epithelial Stem Cell Differentiation. Cell. 2017 Jun 1;169(6):1119-1129.e11.

26. Nosbaum A, Prevel N, Truong H-A, Mehta P, Ettinger M, Scharschmidt TC, et al. Cutting Edge: Regulatory T Cells Facilitate Cutaneous Wound Healing. J Immunol. 2016 Mar 1;196(5):2010–4.

27. Delacher M, Simon M, Sanderink L, Hotz-Wagenblatt A, Wuttke M, Schambeck K, et al. Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. Immunity. 2021 Apr 13;54(4):702-720.e17.

28. Park JS, Kim JH. Role of non-classical T cells in skin immunity. Mol Immunol. 2018 Nov;103:286–92.

29. Mjösberg J, Spits H. Human innate lymphoid cells. J Allergy Clin Immunol. 2016 Nov;138(5):1265–76.

30. Klose CSN, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016 Jun 21;17(7):765–74.

31. Bernink JH, Peters CP, Munneke M, te Velde AA, Meijer SL, Weijer K, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013 Mar;14(3):221–9.

32. Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid cells: partners in host defense. Nat Immunol. 2016 Jun 21;17(7):758–64.

33. Kortekaas Krohn I, Shikhagaie MM, Golebski K, Bernink JH, Breynaert C, Creyns B, et al. Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy. 2018 Apr;73(4):837–50.

34. Mjösberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol. 2011 Sep 11;12(11):1055–62.

35. Flamar A-L, Klose CSN, Moeller JB, Mahlakõiv T, Bessman NJ, Zhang W, et al. Interleukin-33 Induces the Enzyme Tryptophan Hydroxylase 1 to Promote Inflammatory Group 2 Innate Lymphoid Cell-Mediated Immunity. Immunity. 2020 Apr 14;52(4):606-619.e6.

36. Steelant B, Seys SF, Van Gerven L, Van Woensel M, Farré R, Wawrzyniak P, et al. Histamine and T helper cytokine-driven epithelial barrier dysfunction in allergic rhinitis. J Allergy Clin Immunol. 2018 Mar;141(3):951-963.e8.

37. Sugita K, Altunbulakli C, Morita H, Sugita A, Kubo T, Kimura R, et al. Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13. Allergy. 2019;74(12):2534–7.

38. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020 Jan;75(1):54–62.

39. Tojima I, Matsumoto K, Kikuoka H, Hara S, Yamamoto S, Shimizu S, et al. Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D2 and cysteinyl leukotrienes in allergic rhinitis. Allergy. 2019 Dec;74(12):2417–26.

40. Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021 Apr 12;

41. Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018 May;32(5):657–82.

42. Werfel T, Allam J-P, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016 Aug;138(2):336–49.

43. Hijnen, D.J., University Utrecht. T cell behaviour in the pathogenesis of atopic dermatitis : how they get in and how to get them out [Internet]. Utrecht University; 2007 [cited 2021 May 31]. Available from: https://dspace.library.uu.nl/handle/1874/20881

44. Grewe M, Bruijnzeel-Koomen CAFM, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, et al. A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunology Today. 1998 Aug 1;19(8):359–61.

45. Trautmann A, Akdis M, Kleemann D, Altznauer F, Simon HU, Graeve T, et al. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000 Jul;106(1):25–35.

46. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009 Dec;119(12):3573–85.

47. Czarnowicki T, Kim HJ, Villani AP, Glickman J, Duca ED, Han J, et al. High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis. Allergy. 2021 Apr 5;

48. Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, de Guzman Strong C, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015 Nov;136(5):1254–64.

49. Hijnen D, Knol EF, Gent YY, Giovannone B, Beijn SJP, Kupper TS, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22. J Invest Dermatol. 2013 Apr;133(4):973–9.

50. Hennino A, Jean-Decoster C, Giordano-Labadie F, Debeer S, Vanbervliet B, Rozières A, et al. CD8+ T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic dermatitis. Journal of Allergy and Clinical Immunology. 2011 Apr 1;127(4):1064–7.

51. Bohle B, Schwihla H, Hu HZ, Friedl-Hajek R, Sowka S, Ferreira F, et al. Long-lived Th2 clones specific for seasonal and perennial allergens can be detected in blood and skin by their TCR-hypervariable regions. J Immunol. 1998 Feb 15;160(4):2022–7.

52. Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018 Jun 21;4(1):1.

53. Filtjens J, Roger A, Quatrini L, Wieduwild E, Gouilly J, Hoeffel G, et al. Nociceptive sensory neurons promote CD8 T cell responses to HSV-1 infection. Nat Commun. 2021 May 18;12(1):2936.

54. Czarnowicki T, Santamaria-Babí LF, Guttman-Yassky E. Circulating CLA+ T cells in atopic dermatitis and their possible role as peripheral biomarkers. Allergy. 2017 Mar;72(3):366–72.

55. Kakinuma T, Nakamura K, Wakugawa M, Mitsui H, Tada Y, Saeki H, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001 Mar;107(3):535–41.

56. Hijnen D, De Bruin-Weller M, Oosting B, Lebre C, De Jong E, Bruijnzeel-Koomen C, et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol. 2004 Feb;113(2):334–40.

57. Thijs J, Krastev T, Weidinger S, Buckens CF, de Bruin-Weller M, Bruijnzeel-Koomen C, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015 Oct;15(5):453–60.

58. Berth-Jones J, Graham-Brown RA, Marks R, Camp RD, English JS, Freeman K, et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br J Dermatol. 1997 Jan;136(1):76–81.

59. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005 May;60(5):693–6.

60. Siegels D, Heratizadeh A, Abraham S, Binnmyr J, Brockow K, Irvine AD, et al. Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. Allergy. 2021 Apr;76(4):1053–76.

61. Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014 Jul 10;371(2):130–9.

62. Ariëns LFM, van der Schaft J, Bakker DS, Balak D, Romeijn MLE, Kouwenhoven T, et al. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy. 2019 Oct 8;

63. Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016 15;375(24):2335–48.

64. Wollenberg A, Howell MD, Guttman-Yassky E, Silverberg JI, Kell C, Ranade K, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019 Jan;143(1):135–41.

65. Simpson EL, Flohr C, Eichenfield LF, Bieber T, Sofen H, Taïeb A, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018 May;78(5):863-871.e11.

66. Silverberg JI, Toth D, Bieber T, Alexis AF, Elewski BE, Pink AE, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021 Mar;184(3):450–63.

67. Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020 Aug 1;156(8):863–73.

68. Silverberg JI, Simpson EL, Wollenberg A, Bissonnette R, Kabashima K, DeLozier AM, et al. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials. JAMA Dermatol. 2021 May 12;

69. Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020 Jul 25;396(10246):255–66.

70. Guttman-Yassky E, Thaçi D, Pangan AL, Hong HC-H, Papp KA, Reich K, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020 Mar;145(3):877–84.

71. Simpson EL, Lacour J-P, Spelman L, Galimberti R, Eichenfield LF, Bissonnette R, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020 Aug;183(2):242–55.

72. Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab-JP01 Study Group. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. N Engl J Med. 2020 Jul 9;383(2):141–50.

73. Ungar B, Pavel AB, Li R, Kimmel G, Nia J, Hashim P, et al. Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis. J Allergy Clin Immunol. 2021 Jan;147(1):394–7.

74. Bakker DS, Nierkens S, Knol EF, Giovannone B, Delemarre EM, van der Schaft J, et al. Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. J Allergy Clin Immunol. 2021 Jan;147(1):189–98.

75. Valenta R, Steiner R, Seiberler S, Maurer D, Sperr WR, Valent P, et al. Immunoglobulin E Response to Human Proteins in Atopic Patients. Journal of Investigative Dermatology. 1996 Aug 1;107(2):203–8.

76. Tang TS, Bieber T, Williams HC. Does “autoreactivity” play a role in atopic dermatitis? Journal of Allergy and Clinical Immunology. 2012 May 1;129(5):1209-1215.e2.

77. Badloe FMS, De Vriese S, Coolens K, Schmidt-Weber CB, Ring J, Gutermuth J, et al. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy. 2020;10:34.

78. De Bruyn Carlier T, Badloe FMS, Ring J, Gutermuth J, Kortekaas Krohn I. Autoreactive T cells and their role in atopic dermatitis. J Autoimmun. 2021 Apr 20;120:102634.

79. Nograles KE, Zaba LC, Guttman-Yassky E, Fuentes-Duculan J, Suárez-Fariñas M, Cardinale I, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008 Nov;159(5):1092–102.

80. Teunissen MBM, Munneke JM, Bernink JH, Spuls PI, Res PCM, Te Velde A, et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients. J Invest Dermatol. 2014 Sep;134(9):2351–60.

81. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012 Mar 29;366(13):1190–9.

82. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014 Jul 24;371(4):326–38.

83. Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015 Aug 8;386(9993):541–51.

84. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct;373(14):1318–28.

85. Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr;80(4):1029–72.

86. Dyring-Andersen B, Geisler C, Agerbeck C, Lauritsen JPH, Gúdjonsdottir SD, Skov L, et al. Increased number and frequency of group 3 innate lymphoid cells in nonlesional psoriatic skin. Br J Dermatol. 2014 Mar;170(3):609–16.

87. Villanova F, Flutter B, Tosi I, Grys K, Sreeneebus H, Perera GK, et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol. 2014 Apr;134(4):984–91.

88. Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930–9.

89. Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014 Apr;133(4):1032–40.

90. Papp KA, Blauvelt A, Bukhalo M, Gooderham M, Krueger JG, Lacour J-P, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017 Apr 20;376(16):1551–60.

91. Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018 Aug 25;392(10148):650–61.

92. Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic’) urticaria. Br J Dermatol. 2015;172(5):1294–302.

93. Beck LA, Bernstein JA, Maurer M. A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria. Acta Derm Venereol. 2017 Feb 8;97(2):149–58.

94. Hatada Y, Kashiwakura J, Hayama K, Fujisawa D, Sasaki-Sakamoto T, Terui T, et al. Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients. Int Arch Allergy Immunol. 2013;161 Suppl 2:154–8.

95. Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018 Sep;142(3):876–82.

96. Chanprapaph K, Iamsumang W, Wattanakrai P, Vachiramon V. Thyroid Autoimmunity and Autoimmunity in Chronic Spontaneous Urticaria Linked to Disease Severity, Therapeutic Response, and Time to Remission in Patients with Chronic Spontaneous Urticaria. Biomed Res Int. 2018;2018:9856843.

97. Maurer M, Eyerich K, Eyerich S, Ferrer M, Gutermuth J, Hartmann K, et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020 May;181(5):321–33.

98. Auyeung P, Mittag D, Hodgkin PD, Harrison LC. Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iα subunit. J Allergy Clin Immunol. 2016 Sep;138(3):761-768.e4.

99. Chen Q, Zhong H, Chen WC, Zhai Z, Zhou Z, Song Z, et al. Different expression patterns of plasma Th1-, Th2-, Th17- and Th22-related cytokines correlate with serum autoreactivity and allergen sensitivity in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):441–8.

100. Bauer A, Dickel H, Jakob T, Kleinheinz A, Lippert U, Metz M, et al. Expert consensus on practical aspects in the treatment of chronic urticaria. Allergo J Int. 2021;30(2):64–75.

101. Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine. 2019 Oct 3;381(14):1321–32.

102. Lopes A, Machado D, Pedreiro S, Henriques A, Silva I, Tavares B, et al. Different frequencies of Tc17/Tc1 and Th17/Th1 cells in chronic spontaneous urticaria. Int Arch Allergy Immunol. 2013;161(2):155–62.

103. Sabag DA, Matanes L, Bejar J, Sheffer H, Barzilai A, Church MK, et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin Exp Allergy. 2020 Jul;50(7):799–804.

104. Arshi S, Babaie D, Nabavi M, Tebianian M, Ghalehbaghi B, Jalali F, et al. Circulating level of CD4+ CD25+ FOXP3+ T cells in patients with chronic urticaria. Int J Dermatol. 2014 Dec;53(12):e561-566.

105. Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, Forsea A-M, et al. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity. 2009 Jan;42(1):41–9.

106. Yamaguchi K, Yamaguchi A, Onuki Y, Itai M, Kashiwagi C, Takehara K, et al. Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age. Modern Rheumatology. 2021 Jan 2;31(1):177–85.

107. Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, et al. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Modern Rheumatology. 2015 Jan 2;25(1):85–9.

108. Ge Y, Li S, Tian X, He L, Lu X, Wang G. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy. Clin Rheumatol. 2021 Jun;40(6):2311–7.

109. Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A, et al. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Modern Rheumatology. 2021 Jan 2;31(1):141–50.

110. Kurtzman DJB, Wright NA, Lin J, Femia AN, Merola JF, Patel M, et al. Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. JAMA Dermatol. 2016 Aug 1;152(8):944–5.

111. Shimojima Y, Matsuda M, Ishii W, Kishida D, Sekijima Y. T-cell receptor-mediated characteristic signaling pathway of peripheral blood T cells in dermatomyositis and polymyositis. Autoimmunity. 2017 Nov 17;50(8):481–90.

112. Pietschke K, Holstein J, Meier K, Schäfer I, Müller-Hermelink E, Gonzalez-Menendez I, et al. The inflammation in cutaneous lichen planus is dominated by IFN-ϒ and IL-21-A basis for therapeutic JAK1 inhibition. Exp Dermatol. 2021 Feb;30(2):262–70.

113. Damsky W, Wang A, Olamiju B, Peterson D, Galan A, King B. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol. 2020 Jun;145(6):1708-1710.e2.

114. Messingham KAN, Noe MH, Chapman MA, Giudice GJ, Fairley JA. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods. 2009 Jul 31;346(1–2):18–25.

115. Lamberts A, Kotnik N, Diercks GFH, Meijer JM, Di Zenzo G, Pas HH, et al. IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):973–80.

116. Kortekaas Krohn I. The emerging role of autoreactive antibodies in inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2021 Apr;35(4):781–2.

117. Didona D, Scarsella L, Fehresti M, Solimani F, Juratli HA, Göbel M, et al. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders. Front Immunol [Internet]. 2021 Mar 25 [cited 2021 May 31];12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027500/

118. Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019 May;18(5):526–34.

119. Döpp R, Schmidt E, Chimanovitch I, Leverkus M, Bröcker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol. 2000 Apr;42(4):577–83.

120. Borcherding N, Crotts SB, Ortolan LS, Henderson N, Bormann NL, Jabbari A. A transcriptomic map of murine and human alopecia areata. JCI Insight. 2020 Jul 9;5(13).

121. Dai Z, Chen J, Chang Y, Christiano AM. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata. JCI Insight. 2021 Apr 8;6(7).

122. Zhang B-X, Lin M, Qi X-Y, Zhang R-X, Wei Z-D, Zhu J, et al. Characterization of circulating CD8+T cells expressing skin homing and cytotoxic molecules in active non-segmental vitiligo. Eur J Dermatol. 2013 Jun;23(3):331–8.

123. Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su M-W, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014 Feb 12;6(223):223ra23.

124. Kumar S, Marathe S, Dhamija B, Zambare U, Bilala R, Warang S, et al. Presence and the roles of IL-9/Th9 axis in vitiligo. Pigment Cell Melanoma Res. 2021 Apr 8;

125. Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 Jul 11;396(10244):110–20.

126. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–49.

127. Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC, et al. Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):591–6.

128. Clark WH, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969 Mar;29(3):705–27.

129. Ferradini L, Mackensen A, Genevée C, Bosq J, Duvillard P, Avril MF, et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest. 1993 Mar;91(3):1183–90.

130. Mackensen A, Ferradini L, Carcelain G, Triebel F, Faure F, Viel S, et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res. 1993 Aug 1;53(15):3569–73.

131. Clark WH, Elder DE, Guerry D, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989 Dec 20;81(24):1893–904.

132. Pastorfide GC, Kibbi AG, de Roa AL, Barnhill RL, Sober AJ, Mihm MC, et al. Image analysis of stage 1 melanoma (1.00-2.50 mm): lymphocytic infiltrates related to metastasis and survival. J Cutan Pathol. 1992 Oct;19(5):390–7.

133. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–80.

134. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer. 1994 Mar 15;73(6):1731–7.

135. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer. 2014 Feb;14(2):135–46.

136. Kreiter S, Vormehr M, van de Roemer N, Diken M, Löwer M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015 Apr 30;520(7549):692–6.

137. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol. 1989 May 15;142(10):3714–25.

138. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med. 1999 Mar 1;189(5):871–6.

139. Maccalli C, Mortarini R, Parmiani G, Anichini A. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int J Cancer. 1994 Apr 1;57(1):56–62.

140. Thomas WD, Hersey P. CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer. 1998 Jan 30;75(3):384–90.

141. Haabeth OAW, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, et al. How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules? Front Immunol. 2014;5:174.

142. Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med. 2012 Aug;18(8):1248–53.

143. Lu Y, Wang Q, Xue G, Bi E, Ma X, Wang A, et al. Th9 Cells Represent a Unique Subset of CD4+ T Cells Endowed with the Ability to Eradicate Advanced Tumors. Cancer Cell. 2018 Jun 11;33(6):1048-1060.e7.

144. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008 Jul 15;112(2):362–73.

145. Chen C, Gao F-H. Th17 Cells Paradoxical Roles in Melanoma and Potential Application in Immunotherapy. Front Immunol [Internet]. 2019 Feb 8 [cited 2021 May 20];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375889/

146. Végran F, Berger H, Boidot R, Mignot G, Bruchard M, Dosset M, et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol. 2014 Aug;15(8):758–66.

147. Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C, et al. Protective role of the inflammatory CCR2/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol. 2013 Jun 15;190(12):6673–80.

148. Viguier M, Lemaître F, Verola O, Cho M-S, Gorochov G, Dubertret L, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004 Jul 15;173(2):1444–53.

149. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M. Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells. J Surg Res. 2007 Jul;141(1):72–7.

150. Huang B, Pan P-Y, Li Q, Sato AI, Levy DE, Bromberg J, et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006 Jan 15;66(2):1123–31.

151. Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol. 2012 Apr;132(4):1239–46.

152. Benveniste PM, Roy S, Nakatsugawa M, Chen ELY, Nguyen L, Millar DG, et al. Generation and molecular recognition of melanoma-associated antigen-specific human γδ T cells. Science Immunology [Internet]. 2018 Dec 14 [cited 2021 May 20];3(30). Available from: https://immunology.sciencemag.org/content/3/30/eaav4036

153. Donia M, Ellebaek E, Andersen MH, Straten P thor, Svane IM. Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes. OncoImmunology. 2012 Nov 1;1(8):1297–304.

154. Cordova A, Toia F, Mendola CL, Orlando V, Meraviglia S, Rinaldi G, et al. Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas. PLOS ONE. 2012 Nov 26;7(11):e49878.

155. Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. British Journal of Cancer. 2011 Sep;105(6):778–86.

156. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang R-F. Tumor-Infiltrating γδ T Cells Suppress T and Dendritic Cell Function via Mechanisms Controlled by a Unique Toll-like Receptor Signaling Pathway. Immunity. 2007 Aug 24;27(2):334–48.

157. Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, et al. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur J Cancer. 2016 Sep;64:116–26.

158. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N, et al. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res. 1999 Oct 15;59(20):5102–5.

159. De Biasi S, Gibellini L, Lo Tartaro D, Puccio S, Rabacchi C, Mazza EMC, et al. Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy. Nature Communications. 2021 Mar 15;12(1):1669.

160. Vorwald VM, Davis DM, Gulick RJV, Torphy RJ, Borgers JSW, Klarquist J, et al. Circulating CD8+ MAIT cells correlate with improved outcomes in anti-PD1 treated melanoma patients. medRxiv. 2020 Aug 23;2020.08.20.20178988.

161. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 2;364(22):2119–27.

162. Ribas A, Weber JS, Chmielowski B, Comin-Anduix B, Lu D, Douek M, et al. Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial. Clin Cancer Res. 2011 May 1;17(9):2987–96.

163. Rittig SM, Haentschel M, Weimer KJ, Heine A, Muller MR, Brugger W, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011 May;19(5):990–9.

164. Perez MC, Miura JT, Naqvi SMH, Kim Y, Holstein A, Lee D, et al. Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. Ann Surg Oncol. 2018 Dec;25(13):3960–5.

165. Burke EE, Zager JS. Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):469–73.

166. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res. 2009 Mar 15;15(6):2123–9.

167. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NPH, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007 Jun 15;13(12):3630–6.

168. de Gast GC, Klümpen HJ, Vyth-Dreese FA, Kersten MJ, Verra NC, Sein J, et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res. 2000 Apr;6(4):1267–72.

169. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014 Jun 15;192(12):5451–8.

170. Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–65.

171. Peggs KS, Quezada SA. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. Expert Rev Anticancer Ther. 2010 Nov;10(11):1697–701.

172. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013 Oct 1;19(19):5300–9.

173. Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, et al. Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer. Clin Cancer Res. 2018 Apr 15;24(8):1816–23.

174. Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, et al. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clin Cancer Res. 2017 Apr 15;23(8):1929–36.

175. Glisson BS, Leidner RS, Ferris RL, Powderly J, Rizvi NA, Keam B, et al. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 Oct 15;26(20):5358–67.

176. Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, et al. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Jun 20;35(18):2028–36.

177. Schaft N. The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview. Cancers (Basel). 2020 Sep 9;12(9).

178. Verbeke R, Lentacker I, Breckpot K, Janssens J, Van Calenbergh S, De Smedt SC, et al. Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and α-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells. ACS Nano. 2019 Feb 26;13(2):1655–69.

179. Kobayashi E, Motoki K, Uchida T, Fukushima H, Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol Res. 1995;7(10–11):529–34.

180. Exley MA, Friedlander P, Alatrakchi N, Vriend L, Yue S, Sasada T, et al. Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer Res. 2017 Jul 15;23(14):3510–9.

181. Giaccone G, Punt CJA, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002 Dec;8(12):3702–9.

182. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013 Aug 28;5(200):200ra116.

183. Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, et al. PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. Oncoimmunology. 2016;5(11):e1235107.

184. Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018 Feb 1;128(2):805–15.

185. Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017 Apr 3;214(4):895–904.

186. Paulson KG, Lahman MC, Chapuis AG, Brownell I. Immunotherapy for skin cancer. Int Immunol. 2019 Jul 13;31(7):465–75.

187. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res. 2013 Dec;23(6):498–501.

188. Hwang SJE, Carlos G, Wakade D, Sharma R, Fernandez-Penas P. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma. Melanoma Res. 2016 Aug;26(4):417–20.

189. Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017 May;76(5):863–70.

190. Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol. 2016 Jan;152(1):45–51.

191. Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017 Apr;41(2):125–8.

192. Lommerts JE, Teulings H-E, Ezzedine K, van Geel N, Hartmann A, Speeckaert R, et al. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field. J Am Acad Dermatol. 2016 Dec;75(6):1198–204.

193. Teulings H-E, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015 Mar 1;33(7):773–81.

194. Succaria F, Kvistborg P, Stein JE, Engle EL, McMiller TL, Rooper LM, et al. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas. Cancer Immunol Immunother. 2021 May;70(5):1227–37.

195. Seminerio I, Descamps G, Dupont S, de Marrez L, Laigle J-A, Lechien JR, et al. Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2019 Feb 15;11(2).

196. Tabachnick-Cherny S, Pulliam T, Church C, Koelle DM, Nghiem P. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. Mol Carcinog. 2020 Jul;59(7):807–21.

197. Jing L, Ott M, Church CD, Kulikauskas RM, Ibrani D, Iyer JG, et al. Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8+ T Cells within Polyomavirus-Driven Merkel Cell Carcinomas. Cancer Immunol Res. 2020 May;8(5):648–59.

198. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016 Jun 30;374(26):2542–52.

199. Spassova I, Ugurel S, Terheyden P, Sucker A, Hassel JC, Ritter C, et al. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. Clin Cancer Res. 2020 May 1;26(9):2257–67.

200. Lidenge SJ, Tso FY, Ngalamika O, Kolape J, Ngowi JR, Mwaiselage J, et al. Lack of CD8+ T-cell co-localization with Kaposi’s sarcoma-associated herpesvirus infected cells in Kaposi’s sarcoma tumors. Oncotarget. 2020 Apr 28;11(17):1556–72.

201. Joest B, Kempf W, Berisha A, Peyk P, Tronnier M, Mitteldorf C. Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment. J Cutan Pathol. 2020 Oct;47(10):888–95.

**IX Tables:**

**Table 1: Characteristics of innate and adaptive subsets of T-cells and their function.**

CCR: CC chemokine receptor; CXCR: CXC chemokine receptor; GM-CSF: Granulocyte-macrophage colony-stimulating factor; IFN-γ: interferon gamma; ILC: innate lymphoid cell; IPEX: Immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome; Lti: lymphoid tissue inducer cell; NK: natural killer; Tc: cytotoxic T-cell; Tfh: follicular T helper cells; Th: T helper; TNF-α: tumor necrosis factor alpha; Treg: regulatory T-cell.

**Table 2: Available and promising therapeutic approaches to harness T-cells in skin disease.**

CTLA-4: cytotoxic T-lymphocyte antigen-4; IFN-α: interferon alpha; ILC: innate lymphoid cells; JAK: Janus kinase; NK: natural killer; PD-1: programmed cell death-1; PD-L1: ligand of programmed cell death-1; Th: T helper cell; TNF-α: tumor necrosis factor alpha; Treg: regulatory T-cell.

**X Figure legends:**

**Figure 1: Schematic overview of the conventional and unconventional T-cell subsets.**

During the maturation and selection process of T-cells in the thymus, surface markers are differently expressed. Naive T-cells further differentiate to their mature state depending on local cytokines.

**Figure 2: Schematic overview of the functional properties of T-cell subsets under homeostatic condition and inflammatory skin diseases.**

**A.** In healthy skin, both innate and adaptive immune cells are present in low numbers in the dermis. Cutaneous lymphocyte-associated antigen (CLA) is expressed on antigen-specific tissue residing memory T-cells (TRM) or effector memory T-cells (TEM). TEM cells can recirculate to the peripheral blood. CD4+ tissue resident regulatory T-cells are important to maintain the peripheral tolerance. **B.** Type I hypersensitivity is characterized by an IgE-mediated allergic inflammation and T helper (Th)2 polarization. An impaired epidermal barrier function leads to increased access for allergens, which are picked up by antigen-presenting cells (Langerhans cells or dendritic cells) in the epidermis. T-cells that are presented to these antigens express CLA and activate plasma cells to produce IgE in presence of IL-4. Sensitized mast cells respond adequately upon exposure to the allergens resulting in degranulation and release of various mediators, such as histamine, which can contribute to itch and inflammation. Th2-cells and type 2 innate lymphoid cells (ILC) are major sources of IL-5 and IL-13. **C.** Atopic dermatitis is a T-cell-mediated chronic relapsing inflammation of the skin. Th2-cells are the most abundant cells and responsible for the production of the pro-inflammatory cytokines IL-4, IL-5 and IL-13 together with ILC2s. Th2-cells produce IL-31 resulting in itch, which is a hallmark of atopic dermatitis. Also, Th1 and Th22-cells are present, which release interferon (IFN)-γ and IL-22, respectively. **D.** Psoriasis, γδ T-cells, dendritic cells and macrophages affect the Th17 and Tc17 cells, which are the dominating cells, but also Th1 and ILC3s are present. Release of IL-17A, IL-22 and tumor necrosis factor (TNF)-α results in erythematous scaly papules and plaques. **E.** In melanoma, T-cell infiltration is associated with prolonged survival and reduced risk of metastasis. CD4+ Th1v-cells can recognize tumor-associated antigens (TAAs) and kill melanoma cells via production of IFN-γ, perforin and granzyme B. Via the CCL2/CCR2-pathway, unconventional γδ T-cells can recognize tumor-specific ligands. Presence of γδ2 is correlated to good prognosis compared to the presence of γδ1 T-cells, which is linked to bad prognosis. Responders to anti-PD-1 therapy increase CD8+ T-cells and mucosal associated invariant (MAIT) T-cells.

CLA: cutaneous lymphocyte-associated antigen; CTLA4: cytotoxic T-lymphocyte associated antigen 4; IFN-γ: interferon-gamma; ILC: innate lymphoid cell; iNKT: invariant natural killer T; LT4: leukotriene 4; MAIT: mucosal associated invariant T; MHC: major histocompatibility complex; PGD2: Prostaglandin D2; TAA: tumor-associate antigen; Th: T helper; Treg: regulatory T-cell; TRM: tissue-residing memory T; TSLP: thymic stromal lymphopoietin.